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Abstract
Epidemiological studies fairly convincingly suggest that higher intake of fish and omega-3 fatty acids
present in fish is associated with reduced risk for age-related cognitive decline (ARCD). Normally,
docosahexaenoic acid (DHA) in plasma is positively associated with DHA intake. However, despite being
associated with lower fish and DHA intake, unexpectedly, ARCD is not consistently associated with lower
plasma DHA. Furthermore, DHA is often slightly but significantly higher in plasma and erythrocytes in the
elderly without ARCD compared to young adults. Higher plasma DHA in the elderly may be a sign that
their fish or DHA intake is higher but we show here that various aspects of DHA homeostasis also change
with age. Our supplementation and tracer studies show that DHA metabolism, e.g. transit through the
plasma and apparent retroconversion but not beta-oxidation, is different in healthy elderly compared to
healthy young adults. Apolipoprotein E4 increases the risk of ARCD, possibly in part because it changes
DHA homeostasis. Therefore, independent of differences in fish intake, changing DHA homeostasis may
contribute to making the elderly more susceptible to cognitive decline despite them having similar or
sometimes higher plasma DHA than in younger adults. Key words: aging, cognitive decline, dietary,
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Abstract
Epidemiological studies fairly convincingly suggest that higher intake of fish and omega‐3 fatty
acids present in fish is associated with reduced risk for age‐related cognitive decline (ARCD).
Normally, docosahexaenoic acid (DHA) in plasma is positively associated with DHA intake.
However, despite being associated with lower fish and DHA intake, unexpectedly, ARCD is not
consistently associated with lower plasma DHA. Furthermore, DHA is often slightly but
significantly higher in plasma and erythrocytes in the elderly without ARCD compared to young
adults. Higher plasma DHA in the elderly may be a sign that their fish or DHA intake is higher but
we show here that various aspects of DHA homeostasis also change with age. Our
supplementation and tracer studies show that DHA metabolism, e.g. transit through the plasma
and apparent retroconversion but not beta‐oxidation, is different in healthy elderly compared
to healthy young adults. Apolipoprotein E4 increases the risk of ARCD, possibly in part because
it changes DHA homeostasis. Therefore, independent of differences in fish intake, changing DHA
homeostasis may contribute to making the elderly more susceptible to cognitive decline despite
them having similar or sometimes higher plasma DHA than in younger adults.
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DHA and aging‐related cognitive decline
Cognitive health in the elderly is an increasingly important preoccupation for public
health institutions globally. This preoccupation is all the more acute given the lack of effective
medical treatment for the various types of cognitive decline associated with aging including
‘Alzheimer’s disease’. Because the various forms of cognitive decline in the elderly are
increasingly recognised as a heterogeneous conditions (Whitehouse et al. 2011), we prefer the
general term ‐ aging‐related cognitive decline (ARCD). Conditions linked to the metabolic
syndrome, particularly insulin resistance and type 2 diabetes, are major risk factors for cognitive
decline in the elderly (Hao et al. 2011). Since the metabolic syndrome is preventable at least in
adolescents and younger adults, in theory, prevention should be able to play a key role in the
reducing the risk of ARCD. Nutrition and physical activity are key elements of prevention in
reducing the susceptibility to the metabolic syndrome and type 2 diabetes. Omega‐3 fatty acids
such as docosahexaenoic acid (DHA) are amongst the nutrients of particular interest relative to
optimal glucose metabolism, especially for cognition (Cunnane et al. 2009; Pifferi et al. 2010;
Cunnane et al. 2011).
Our aim here is to draw attention to an apparent dichotomy: On the one hand, there is
the relatively solid evidence that low fish and low DHA intake are common in ARCD; on the
other hand, there is the lack of consistent evidence that brain or plasma omega‐3 fatty acids,
particularly DHA, are any different in ARCD than in age‐matched controls (Cunnane et al. 2009).
Furthermore, some studies show a benefit on cognitive function of higher intake of fish or DHA
3
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in the elderly (Beydoun et al. 2007; Dullemeijer et al. 2007), but others did not observe any
difference in cognitive performance (Van De Rest et al. 2008; Dangour et al. 2010). These
observations seem contradictory and counter‐intuitive: Why is it that if fish intake is low in
ARCD, and if fish intake is an important predictor of plasma DHA, that plasma DHA is not more
consistently reported to be lower in ARCD? Equally if not more importantly, can omega‐3
supplements correct an apparent DHA deficit in the elderly and thereby reduce the risk of ARCD
and, if so, under what conditions, because presently the outcomes of such studies have not
been too promising (Freund‐Levi et al. 2006; Fotuhi et al. 2009; Quinn et al. 2010).
We have previously raised some methodological issues that may contribute to this
apparent dichotomy between the epidemiological versus the biological evidence for a
protective role of fish and/or DHA in ARCD (Cunnane et al. 2009) and will discuss here some
potential biological reasons for this inconsistency. Our focus here is not so much on ARCD per se
but on the healthy elderly because clear indications are emerging that omega‐3 fatty acid, at
least DHA, metabolism changes in the elderly with no symptoms of ARCD.

Plasma DHA response to a DHA‐rich supplement
We and others have observed that the healthy elderly tend to have 10‐15% higher DHA
and eicosapentaenoic acid (EPA) in plasma (Dewailly et al. 2003; Crowe et al. 2008; Fortier et al.
2010; Yanagisawa et al. 2010) and red blood cells (De Groot et al. 2009), but there are
exceptions (Babin et al. 1999; Sfar et al. 2010). Somewhat higher plasma DHA may be due in
part to higher DHA intakes in the elderly (Meyer et al. 2003; Buyken et al. 2010). Given that we
4
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have not tracked DHA intakes in our elderly study participants (Fortier et al. 2010), we did not
know whether the higher plasma EPA and DHA were due to higher fish and seafood intake in
the elderly or to an aging‐related change in DHA metabolism. We decided to probe the
possibility of an aging‐related change in DHA metabolism with a simple three week
supplementation study in which participants received about 680 mg DHA /day, which is about 4‐
5 times usual intake in many developed countries (Kris‐Etherton et al. 2009; Lucas et al. 2010;
Meyer 2011). Participants were screened to eliminate those already consuming high amounts of
fish or fish oil supplements. Interestingly, despite almost identical fasting DHA at baseline, after
3 weeks supplementation, the elderly participants had a 42% higher plasma response to the
same supplement as the young participants (Figure 1) ((Vandal et al. 2008). This was a
preliminary indication to us that perhaps DHA metabolism was changing with healthy aging, e.g.
independently of ARCD.

Carbon‐13‐labelled DHA transit through plasma
The fish oil supplementation study (Vandal et al. 2008) led us to examine metabolism of
carbon‐13 (13C)‐DHA in the healthy elderly. Again, we were surprised to see a very significant
difference in the transit of a single oral 50 mg dose of

13

C‐DHA through the plasma with

repeated blood sampling over a 4 week study period. The elderly had slower DHA transit in the
form of higher

13

C‐DHA enrichment in all plasma lipid pools examined. This slower clearance

was observed in the pools rapidly labeled in the first hours after the oral dose, ex. free fatty
acids and triglycerides, as well as in those pools increasingly labeled days to weeks later, ex.
5
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phospholipids and cholesteryl esters (Figure 2) (Plourde et al. 2011). These results support the
idea that higher plasma DHA (fasting or response to a fish oil supplement) in the elderly is not
necessarily an indication of ‘better’ DHA metabolism, better DHA status or even higher intake of
DHA; it may well be that aging changes DHA homeostasis in a way that slows down its transfer
to tissues including the brain thus increasing its levels in plasma, at least transiently. This
apparent delay in DHA transport into tissues may underlie and contribute to the increased
susceptibility to cognitive decline in the elderly.

Other components of homeostasis
13

C‐DHA provides an opportunity to measure other components of DHA homeostasis

besides plasma levels, including beta‐oxidation, retroconversion, and conversion to bioactive
metabolites. One day after an oral dose of 13C‐DHA, about 7% of it is completely beta‐oxidized
to CO2 (Plourde et al. 2011), which is about 30% of the beta‐oxidation of the same dose of 13C‐
linoleic acid and about 25% of that of 13C‐alpha‐linolenic acid given under the same conditions.
Seven days after giving the oral dose of 13C‐DHA, about 35% is beta‐oxidized (Figure 3), whereas
13

C‐linoleic acid and

13

C‐alpha‐linolenic acid are beta‐oxidized at 40% and 70%, respectively

(McCloy et al. 2004). Up to seven days post‐dose, beta‐oxidation of 13C‐DHA does not seem to
be affected by healthy aging. However, the apparent retroconversion of 13C‐DHA to 13C‐EPA is
roughly doubled (from 2.0 to 4.3 %) in the healthy elderly. Based on our one month study,
apparent retroconversion appears to draw no more than 5‐7% of 13C‐DHA metabolism (Plourde
et al. 2011).
6
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Genotype (apo E)
Whalley et al (2008) were the first to suggest that apolipoprotein (apo) E genotype might
affect DHA metabolism; they reported that cognitive decline was associated with lower
erythrocyte omega–3 fatty acid content only in the presence of the apo E4 allele. We have also
observed that apo E genotype influences plasma EPA and DHA after a fish oil supplement, with
apo E4 significantly reducing the rise in plasma DHA after 6 wk of fish oil supplementation that
provided 1.9 mg/d of EPA and 1.1 mg/d of DHA (Plourde et al. 2009).
We have not yet assessed the relationship between DHA metabolism and apo E
genotype in the elderly but given that apo E4 predisposes to various forms of ARCD (Song et al.
2009; Leoni 2011), this interaction bears further scrutiny. As suggested by Whalley et al (2008),
one potential explanation of a relation between omega‐3 fatty acids and apo E genotype would
be increased oxidative stress that catabolises DHA. Studies in vitro (Miyata et al. 1996; Jolivalt et
al. 2000) and in mice (Ramassamy et al. 2000) and humans (Kharrazi et al. 2008) suggest that
apo E4 carriers have greater susceptibility to oxidative damage and lower antioxidant defenses.

Relation between dietary and plasma DHA
If lower habitual fish and/or DHA intake increase the risk of ARCD (reviewed by Cunnane
et al. 2009) but this is not reflected by lower plasma DHA in ARCD, then the relation between
dietary and plasma DHA in the elderly and in ARCD needs further attention. Our preliminary
assessment of several published papers on this topic shows the anticipated and relatively
7
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consistent positive, dose‐dependent relation between DHA intake and plasma DHA (Figure 4)
(Blonk et al. (1990). We believe that a crucial point needing verification is whether ARCD is
associated with a leftward shift in the diet‐plasma relationship for DHA (Figure 5). This
possibility is suggested by at least three observations: (i) the lack of consistently lower plasma
DHA in the elderly with ARCD (Cunnane et al. 2009), (ii) the higher plasma DHA and

13

C‐DHA

response in the healthy elderly (Vandal et al. 2008; Plourde et al. 2011), and (iii) the similar
plasma DHA levels but lower DHA intake in those with ARCD (Lopez et al. (2010). We see this as
a topic for fruitful investigation and, at the moment, draw no firm conclusion as to whether this
key component of DHA homeostasis, i.e. plasma response to habitual dietary DHA intake, is
altered by healthy aging or cognitive decline in the elderly.

Conclusions
Although both prospective and cross‐sectional epidemiological studies clearly associate
ARCD with lower fish and DHA intake, ARCD is not consistently associated with lower plasma
DHA (Cunnane et al 2009). Indeed, DHA is often slightly but significantly higher in plasma and
erythrocytes in the elderly compared to young adults even though the former are at increased
risk of ARCD. Higher plasma DHA in the elderly is not necessarily a sign that their fish intake is
higher; we review here several of our studies showing that DHA homeostasis appears to change
with age. Our tracer and supplementation studies show that DHA metabolism, i.e. transit
through the plasma and apparent retroconversion, changes with aging in the absence of ARCD.
Apo E4 increases the risk of ARCD, and our studies show that this may be in part because it
8
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changes DHA homeostasis. Independent of differences in fish intake, changing DHA homeostasis
may contribute to making the elderly more susceptible to cognitive decline despite them having
similar or even somewhat higher plasma DHA than in younger adults. Identifying how and why
DHA homeostasis changes with age may contribute to resolving the problems with clinical trials
that have unsuccessfully used fish oil or DHA supplements to treat ARCD.
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Figure 1: DHA in plasma total lipids in healthy young and elderly humans (24 ± 2 and 74 ± 4 years old, respectively)
during a 3 week dietary supplementation with fish providing 680 mg/d DHA, as adapted from Vandal et al (2008).
At the end of the supplementation period, plasma DHA was 42% higher in the elderly group than in the young
group (* p < 0.05).
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Figure 2

Figure 2: Healthy aging delays plasma clearance of 13C‐DHA as adapted from Plourde et al (2011). In the elderly,
plasma tracer concentration in free fatty acids (FFA) and triglycerides (TG) was 4‐5 fold higher 4 h after giving the
50 mg oral dose whereas in phospholipids (PL) and cholesteryl esters (CE), 13C‐DHA was 2‐fold higher 1‐4 weeks
later (Young: 26.8 ± 2.6 years ; Elderly 76.5 ± 2.7 years).
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Figure 3
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Figure 3: Slower beta‐oxidation of 13C‐docosahexaenoic acid (DHA) compared to 13C‐linoleate and 13C‐α-linolenate
over 1 and 7 d. Adapted from McCloy et al (2004) and Plourde et al (2011).
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Figure 4

Figure 4: Near linear relation between dietary and plasma DHA at DHA intakes below 1000 mg/d (Sanders et al.
1989; Arterburn et al. 2006; Sublette et al. 2007; Sun et al. 2007; Lopez et al. 2010; Swierk et al. 2011).
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Figure 5
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Figure 5: Dietary verses plasma DHA in aging‐related cognitive decline (ARCD), based on Lopez et al (2010). In Lopez
et al (2010), daily intake of 90 mg DHA in the elderly was associated with cognitive decline (ARCD+), whereas 160
mg of DHA was associated with an absence of cognitive decline (ARCD‐), yet % DHA in plasma total lipids was not
significantly different in the two groups. Though by no means conclusive, these data support our hypothesis that
there may be a shift in DHA homeostasis in the elderly with ARCD.
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